BIOMAT Database Logo BIOMAT Database Logo

[Biochemical and physiological activity of new peptide inhibitors of angiotensin-converting enzyme]. 1996

O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D008526 Medulla Oblongata The lower portion of the BRAIN STEM. It is inferior to the PONS and anterior to the CEREBELLUM. Medulla oblongata serves as a relay station between the brain and the spinal cord, and contains centers for regulating respiratory, vasomotor, cardiac, and reflex activities. Accessory Cuneate Nucleus,Ambiguous Nucleus,Arcuate Nucleus of the Medulla,Arcuate Nucleus-1,External Cuneate Nucleus,Lateral Cuneate Nucleus,Nucleus Ambiguus,Ambiguus, Nucleus,Arcuate Nucleus 1,Arcuate Nucleus-1s,Cuneate Nucleus, Accessory,Cuneate Nucleus, External,Cuneate Nucleus, Lateral,Medulla Oblongatas,Nucleus, Accessory Cuneate,Nucleus, Ambiguous,Nucleus, External Cuneate,Nucleus, Lateral Cuneate
D008861 Microsomes Artifactual vesicles formed from the endoplasmic reticulum when cells are disrupted. They are isolated by differential centrifugation and are composed of three structural features: rough vesicles, smooth vesicles, and ribosomes. Numerous enzyme activities are associated with the microsomal fraction. (Glick, Glossary of Biochemistry and Molecular Biology, 1990; from Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) Microsome
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Antioxidant activity of peptide-based angiotensin converting enzyme inhibitors.
March 2012, Organic & biomolecular chemistry,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.
September 1985, Journal of medicinal chemistry,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Peptide inhibitors of pulmonary angiotensin I converting enzyme.
September 1971, Biochimica et biophysica acta,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Novel peptide inhibitors of angiotensin-converting enzyme 2.
May 2003, The Journal of biological chemistry,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions.
January 1984, CRC critical reviews in biochemistry,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Synthesis and antienzymic activity of two new angiotensin converting enzyme inhibitors.
January 1991, Polish journal of pharmacology and pharmacy,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
New potent inhibitors of angiotensin converting enzyme.
January 1984, FEBS letters,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
[Angiotensin converting enzyme-angiotensin II system, atherosclerosis, and angiotensin-converting enzyme inhibitors].
January 2000, Terapevticheskii arkhiv,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
[The antianginal activity of angiotensin-converting enzyme inhibitors].
January 1997, Likars'ka sprava,
O A Gomazkov, and V F Pozdnev, and E V Kalinina, and N V Komissarova, and N A Medvedeva, and M A Nesterova, and O P Petriĭ
Angiotensin converting enzyme inhibitors.
April 1990, American journal of hypertension,
Copied contents to your clipboard!